AMGN
Amgen Inc.
AMGN's fundamentals are strong, but it looks expensive: trading at 27x earnings, above its usual 22x. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AMGN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Stable |
AMGN's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AMGN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $319 | -32% |
| Forward | 19x | $467 | — |
| Fair | 22x | $381 | -18% |
| Expensive | 27x | $465 | -0.5% |
| Current | 27x | $467 | — |
Historical ranges are pointers, not guarantees.
AMGN's PE is in its expensive range at 27x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AMGN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
AMGN has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AMGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.33 | +41% |
| Q3 2026 | $17.24 | +33% |
| Q2 2026 | $16.09 | +31% |
| Q1 2026 | $14.37 | +31% |
| Q4 2025 | $14.23 | +88% |
| Q3 2025 | $12.95 | +66% |
| Q2 2025 | $12.24 | +111% |
| Q1 2025 | $10.97 | +57% |
| Q4 2024 | $7.56 | -39% |
AMGN has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AMGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.4B | +8.5% |
| Q2 2026 | $10.1B | +9.5% |
| Q1 2026 | $8.6B | +5.8% |
| Q4 2025 | $9.9B | +8.6% |
| Q3 2025 | $9.6B | +12% |
| Q2 2025 | $9.2B | +9.4% |
| Q1 2025 | $8.1B | +9.4% |
| Q4 2024 | $9.1B | +11% |
AMGN's revenue has grown year over year for 14 quarters in a row: $10.4B last quarter, up 8.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 36% | +9.4 points |
| Q2 2026 | 35% | +6 points |
| Q1 2026 | 31% | +17 points |
| Q4 2025 | 28% | +2.1 points |
| Q3 2025 | 26% | +2.4 points |
| Q2 2025 | 29% | +6.2 points |
| Q1 2025 | 14% | +1.2 points |
| Q4 2024 | 25% | +9.9 points |
AMGN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AMGN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AMGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | -14% |
| Q2 2026 | $3.5B | +83% |
| Q1 2026 | $1.5B | +51% |
| Q4 2025 | $961M | -78% |
| Q3 2025 | $4.2B | +28% |
| Q2 2025 | $1.9B | -14% |
| Q1 2025 | $980M | +114% |
| Q4 2024 | $4.4B | +1422% |
AMGN's free cash flow has been positive every quarter for seven years: $9.6B over the past year, down 17% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AMGN on cash flow, with more consistent year-over-year improvement.
AMGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +2M shares |
| 1 year | +0.7% | +4M shares |
| 3 years | +1.5% | +8M shares |
| 5 years | -4.2% | -24M shares |
| Available history | -10% | -63M shares |
AMGN has 546M diluted shares, up 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | $6.4B |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AMGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AMGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.7x | Moderate |
| Q2 2026 | 3.1x | Elevated |
| Q1 2026 | 3.4x | Elevated |
| Q4 2025 | 3.8x | Elevated |
| Q3 2025 | 3.8x | Elevated |
| Q2 2025 | 3.8x | Elevated |
| Q1 2025 | 3.7x | Elevated |
| Q4 2024 | 3.8x | Elevated |
AMGN's net debt is about 2.7 years of its operating earnings (EBITDA), down from 3.8 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AMGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.2 | Neutral |
| Stochastic | 84.5 | Overbought |
AMGN's weekly RSI is 67 (neutral) and its Stochastic is 85 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AMGN PE vs Healthcare Sector
| Metric | AMGN | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 26x | 4.8% above |
| PE % | 84 | 29 | 55 pts above |
AMGN is trading at 27x earnings, in line with the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AMGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $437.2 | 6.8% above |
| 20 week MA | $413.1 | 13% above |
| 50 week MA | $373.0 | 25% above |
| 100 week MA | $332.6 | 40% above |
| 200 week MA | $304.8 | 53% above |
AMGN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AMGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $241.5 | $222.9 | -7.7% |
| 2021 | $222.9 | $223.8 | +0.4% |
| 2022 | $223.8 | $263.9 | +18% |
| 2023 | $263.9 | $288.0 | +9.1% |
| 2024 | $288.0 | $262.7 | -8.8% |
| 2025 | $262.7 | $332.9 | +27% |
| 2026 YTD | $332.9 | $467.1 | +40% |
AMGN has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.